Here are our picks for the top-five most significant U.S. biosimilar market developments in 2018: 1. 2018 Sets New Records for Biosimilar Approvals and Launches When 2018 began, nine biosimilars had received FDA approval, and only three were on the U.S. market. This past year saw a record-breaking seven FDA…